2023 World Conference on Lung Cancer (Posters)-EP11.03. Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis

EP11.03. Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis - PDF(Slides)

Pdf Summary

Summary Not Available

Asset Subtitle

Adam Lee

Meta Tag

Speaker Adam Lee

Topic Metastatic NSCLC: Immunotherapy - Retrospective